Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (DE:SP4P)
FRANKFURT:SP4P
Achieve Life Sciences (SP4P) Stock Price & Analysis
1 Followers
SP4P Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.84 - €8.00
Previous Close€4.18
Volume0.00
Average Volume (3M)516.00
Market Cap
€153.13M
Enterprise Value€154.23M
Total Cash (Recent Filing)$15.55M
Total Debt (Recent Filing)$16.73M
Price to Earnings (P/E)N/A
Beta1.29
Next Earnings
Aug 08, 2024EPS Estimate
-€0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,341,303
10 Day Avg. Volume2
30 Day Avg. Volume516
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-43.03
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.77
Forecast
1Y Price Target
€16.69Price Target Upside299.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Achieve Life Sciences News
Bulls Say, Bears Say
Bulls Say
Drug Efficacy And SafetyCytisinicline demonstrated significantly improved quit rates over placebo with a better safety and tolerability profile in Phase III trials, marking a potential breakthrough for smokers seeking cessation.
Financial StabilityAchieve Life Sciences boasts a robust financial position, with enough cash to fund operations into 2026, ensuring continued progress in the development and potential commercialization of cytisinicline.
Market OpportunityWith approximately 34 million American smokers looking to quit, Achieve Life Sciences's cytisinicline has a significant market opportunity, especially following the withdrawal of Pfizer's Chantix from the U.S. market.
Bears Say
Approval DelayAnticipate a one-year delay in cytisinicline's approval and launch, resulting in a lowered price target from $35 to $25.
Data RequirementsThe agency is now looking for >300 and >100 patients' safety data for six- and 12-months, respectively.
Regulatory ChallengesFDA insisting on a longer-term exposure study to further validate the safety profile of cytisinicline, having rejected the sequential dosing represented by the 12-week arms of the Phase 3 studies.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
9.52% Other Institutional Investors
90.48% Public Companies and
Individual Investors
SP4P FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was €2.84 and its highest was €8.00 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Currently, no data Available
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Aug 08, 2024 which is in 86 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on May 09, 2024. The company reported -€0.242 earnings per share for the quarter, missing the consensus estimate of -€0.225 by -€0.017.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -€0.23.
How many shares outstanding does Achieve Life Sciences Inc have?
Currently, no data Available
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -€0.242 in its last earnings report, missing expectations of -€0.225. Following the earnings report the stock price went down -3.981%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in DE:SP4P
---
Achieve Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€16.69 (299.67% Upside)
€16.69 (299.67% Upside)
Blogger Sentiment
Bullish
DE:SP4P Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $91.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.48%
12-Months-Change
Fundamentals
Return on Equity
-109.49%
Trailing 12-Months
Asset Growth
236.71%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
---
SP4P Earnings Call
Q1 2024
0:00 / 0:00
---
SP4P Stock 12 Month Forecast
Average Price Target
€16.69
▲(299.67% Upside)
Technical Analysis
Achieve Life Sciences
―
Aileron Therapeutics
―
Citius Pharmaceuticals
―
Phio Pharmaceuticals
―
Rockwell Med
―
Best Analysts Covering SP4P
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+12.08%
reiterated a buy rating 5 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +12.08% per trade.
---